 Warfarin
"Warfarin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
| Descriptor ID |
D014859
|
| MeSH Number(s) |
D03.383.663.283.446.520.914 D03.438.150.446.520.914
|
| Concept/Terms |
Warfarin- Warfarin
- 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
Coumadine- Coumadine
- Bailly Brand of Warfarin Sodium
Warfant- Warfant
- Antigen Brand of Warfarin Sodium
Coumadin- Coumadin
- Goldshield Brand of Warfarin Sodium
- Marevan
- Boots Brand of Warfarin Sodium
- Bristol-Myers Squibb Brand of Warfarin Sodium
Aldocumar- Aldocumar
- Aldo Brand of Warfarin Sodium
Tedicumar- Tedicumar
- Estedi Brand of Warfarin Sodium
|
Below are MeSH descriptors whose meaning is more general than "Warfarin".
Below are MeSH descriptors whose meaning is more specific than "Warfarin".
This graph shows the total number of publications written about "Warfarin" by people in this website by year, and whether "Warfarin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2014 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Warfarin" by people in Profiles.
-
Claudio-Campos KI, Gonz?lez-Santiago P, Renta JY, Rodr?guez J, Carrasquillo K, Gaedigk A, Roche A, Ducong? J. CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements. Pharmacogenomics. 2019 01; 20(1):3-8.
-
Wagner J, Abdel-Rahman SM. Oseltamivir-warfarin interaction in hypoplastic left heart syndrome: case report and review. Pediatrics. 2015 May; 135(5):e1333-6.
-
Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatr Blood Cancer. 2014 Jun; 61(6):1055-62.
-
Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis. 2009 Jul-Aug; 43(1):119-28.
-
Goldstein JA, Blaisdell JA, Limdi NA. A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy. Blood Cells Mol Dis. 2009 Mar-Apr; 42(2):155-8.
-
Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008 Feb; 83(2):312-21.
-
Kim MJ, Nafziger AN, Kashuba AD, Kirchheiner J, Bauer S, Gaedigk A, Bertino JS. Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. Eur J Clin Pharmacol. 2006 Jun; 62(6):431-6.
-
Shelepova T, Nafziger AN, Victory J, Kashuba AD, Rowland E, Zhang Y, Sellers E, Kearns G, Leeder JS, Gaedigk A, Bertino JS. Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol. 2005 Dec; 45(12):1413-21.
-
Ma JD, Nafziger AN, Kashuba AD, Kim MJ, Gaedigk A, Rowland E, Kim JS, Bertino JS. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers. J Clin Pharmacol. 2004 Jun; 44(6):570-6.
-
Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther. 2003 Nov; 74(5):437-47.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|